ÂÜÀòÂÒÂ×

Kathy LaPorte is an accomplished board director and business leader with extensive experience in the biotechnology and healthcare sectors. Currently serving as a board director and compensation committee chair at 89bio and CERo Therapeutics, and as audit committee chair at Q32 Bio, Bolt Biotherapeutics, and Precipio, Kathy LaPorte brings their expertise to various organizations. Previous roles include CEO and Chief Business Officer at Nodality Inc., where responsibility encompassed overall operations and strategy, and founding partner at New Leaf Venture Partners, focused on healthcare venture capital investing. Kathy LaPorte holds an MBA from Stanford University and a B.S. in Biology from Yale University.